GOLDMAN SACHS GROUP INC - NGM BIOPHARMACEUTICALS INC ownership

NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of NGM BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$292,496
-52.3%
273,361
+15.5%
0.00%
Q2 2023$613,147
-21.2%
236,736
+24.1%
0.00%
Q1 2023$778,476
-59.2%
190,803
-49.7%
0.00%
Q4 2022$1,905,883
-56.3%
379,658
+13.8%
0.00%
-100.0%
Q3 2022$4,364,000
+97.6%
333,639
+93.7%
0.00%
Q2 2022$2,208,000
-11.7%
172,206
+5.1%
0.00%
-100.0%
Q1 2022$2,500,000
-31.7%
163,918
-20.7%
0.00%0.0%
Q4 2021$3,663,000
-30.7%
206,814
-17.8%
0.00%0.0%
Q3 2021$5,286,000
+363.7%
251,485
+334.9%
0.00%
Q2 2021$1,140,000
-23.7%
57,823
+12.5%
0.00%
Q1 2021$1,494,000
+2.8%
51,381
+7.0%
0.00%
Q4 2020$1,454,000
+72.1%
48,025
-9.6%
0.00%
Q3 2020$845,000
-29.2%
53,122
-12.0%
0.00%
Q2 2020$1,193,000
+117.3%
60,396
+35.6%
0.00%
Q1 2020$549,000
-65.7%
44,533
-48.5%
0.00%
Q4 2019$1,600,000
+111.9%
86,519
+58.7%
0.00%
Q3 2019$755,000
-8.3%
54,512
-3.0%
0.00%
Q2 2019$823,00056,2030.00%
Other shareholders
NGM BIOPHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Greenspring Associates, LLC 1,573,357$47,665,00061.89%
RHO CAPITAL PARTNERS INC 3,766,666$114,111,00060.06%
Column Group LLC 15,396,116$466,502,00042.31%
Ponoi II Management, LLC 1,298,908$39,357,00028.68%
Ponoi Management, LLC 1,298,908$39,357,00022.52%
Euclidean Capital LLC 2,083,602$63,133,00013.36%
Aquilo Capital Management, LLC 1,005,534$30,463,0006.33%
Octagon Capital Advisors LP 75,227$2,279,0000.79%
Jasper Ridge Partners, L.P. 308,750$9,354,0000.41%
Point72 Asset Management, L.P. 1,761,157$53,354,0000.26%
View complete list of NGM BIOPHARMACEUTICALS INC shareholders